Table 3 Summary risk estimates of the association between parity number and pancreatic cancer risk
From: Parity and pancreatic cancer risk: evidence from a meta-analysis of twenty epidemiologic studies
2 | > 2 and <5 | ≥5 | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No. of reports | RR (95%CI) | P | I 2 | Ph* | No. of reports | RR (95%CI) | P | I 2 | Ph* | No. of reports | RR (95%CI) | P | I 2 | Ph* | |
Overall | 11 | 0.86 (0.80–0.93) | <0.01 | 8.7 | 0.36 | 28 | 0.98 (0.89–1.09) | 0.75 | 53.7 | <0.01 | 11 | 0.95 (0.75–1.20) | 0.64 | 66.3 | <0.01 |
Subgroup analysis | |||||||||||||||
Study design | |||||||||||||||
Cohort | 6 | 0.87 (0.77–0.99) | 0.04 | 45.3 | 0.10 | 15 | 0.99 (0.88–1.11) | 0.83 | 58.0 | <0.01 | 7 | 0.93 (0.72–1.20) | 0.56 | 63.6 | 0.01 |
Case-control | 5 | 0.89 (0.76–1.04) | 0.14 | 0.0 | 0.83 | 13 | 0.95 (0.78–1.16) | 0.60 | 49.3 | 0.02 | 4 | 0.93 (0.52–1.66) | 0.80 | 73.8 | 0.01 |
Number of cases | |||||||||||||||
<100 | 5 | 0.89 (0.73–1.10) | 0.29 | 0.0 | 0.80 | 21 | 1.05 (0.92–1.21) | 0.46 | 38.8 | 0.04 | 11 | 0.95 (0.75–1.20) | 0.64 | 66.3 | <0.01 |
>100 | 6 | 0.87 (0.78–0.97) | 0.02 | 44.9 | 0.11 | 7 | 0.90 (0.79–1.02) | 0.08 | 64.0 | 0.01 | 0 | - | - | - | - |
Location | |||||||||||||||
Europe | 5 | 0.84 (0.76-0.93) | <0.01 | 14.5 | 0.33 | 12 | 0.96 (0.83–1.12) | 0.64 | 63.8 | <0.01 | 2 | 1.33 (0.96–1.84) | 0.09 | 16.1 | 0.28 |
NorthAmerica | 5 | 0.94 (0.84–1.07) | 0.35 | 0.0 | 0.86 | 15 | 1.04 (0.93–1.17) | 0.47 | 20.8 | 0.22 | 7 | 0.81 (0.65–1.01) | 0.06 | 47.0 | 0.08 |
